1. 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results. (December 2022) Authors: Peters, S.; Lim, S.M.; Ortega Granados, A.L.O.; Pinto, G.D.J.; Fuentes, C.S.; Lo Russo, G.; Schenker, M.; Ahn, J.S.; Reck, M.; Szijgyarto, Z.; Huseinovic, N.; Zografos, E.; O'Donnell, S.; de Marinis, F. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗